Metis Global Partners LLC Sells 307 Shares of Qiagen (NYSE:QGEN)

Metis Global Partners LLC trimmed its position in Qiagen (NYSE:QGEN) by 4.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,623 shares of the company’s stock after selling 307 shares during the quarter. Metis Global Partners LLC’s holdings in Qiagen were worth $298,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares during the period. Toronto Dominion Bank acquired a new position in Qiagen during the second quarter worth $27,000. Massmutual Trust Co. FSB ADV raised its stake in Qiagen by 39.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after acquiring an additional 243 shares in the last quarter. CWM LLC lifted its holdings in shares of Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after acquiring an additional 269 shares during the period. Finally, Headlands Technologies LLC boosted its stake in shares of Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after purchasing an additional 2,189 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Qiagen Stock Performance

QGEN stock opened at $40.99 on Tuesday. The company has a 50 day moving average price of $43.85 and a 200 day moving average price of $43.77. Qiagen has a fifty-two week low of $39.03 and a fifty-two week high of $47.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.46. The stock has a market capitalization of $9.35 billion, a PE ratio of 105.10, a price-to-earnings-growth ratio of 3.14 and a beta of 0.41.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Robert W. Baird lifted their target price on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Qiagen has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.